Crowdfunding sites raise millions for dubious healthcare treatments

The high cost of healthcare services and treatments have led many individuals to turn to crowdfunding sites to help pay for the cost of care. However, these fundraising campaigns are sometimes raising money for less-than-credible treatments, according to a research letter published in JAMA.

The findings come at a time when healthcare costs have continued to outpace other areas of growth and have become an increasingly important issue to Americans. Many Americans also choose to delay care because they cannot afford it, a recent survey found.

While crowdfunding can help cover costs not paid for by insurance, scientifically unsupported, ineffective or potentially dangerous treatments are being thrown in the mix. The prevalence of these campaigns is also growing. In 2016, the largest medical crowdfunding platform, GoFundMe, raised $3 billion across its campaigns, compared to $1 billion in 2015.

Researchers led by Ford Vox, MD, with the medical ethics committee at the Shepard Center in Atlanta, analyzed four different crowdfunding platforms, including 1,636 campaigns, of which 1,059 intended to fund one of five selected treatments.

These five treatments, which are unsupported by evidence or are potentially unsafe, raised more than $6.7 million, according to the analysis. A separate study also found that more than $1 million was raised across 408 campaigns for “unproven stem cell interventions,” researchers noted.

“These results reveal that a wide scope of campaigns for unsupported, ineffective or potentially dangerous treatments are moderately successful in obtaining funding,” the letter concluded. “Assuming that the funds raised are spent to pay for these treatments, donors indirectly contributed millions of dollars to practitioners to deliver dubious, possibly unsafe care.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.